Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
Portfolio Pulse from
VolitionRx Limited announced that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality in sepsis patients, potentially impacting its stock positively.
January 30, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VolitionRx Limited's Nu.Q® NETs H3.1 biomarker has been identified as an independent predictor of 28-day mortality in sepsis patients, which could enhance the company's reputation and market position in the medical diagnostics field.
The study's results highlight the potential of VolitionRx's biomarker in improving sepsis treatment outcomes, which could lead to increased adoption and sales, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100